No Added Benefit of Nonsteroidal Anti-Inflammatory Drug Prophylaxis Beyond 15 Days for Heterotopic Ossification After Hip Arthroscopy Authors: Muge Kirac, Tahir Koray Yozgatlı, Rauf Alizada, Enis Yildirim, Gokhan Polat, Asim Kayaalp, Baris Kocaoglu Published: 2026 ABSTRACT AbstractBackground:Heterotopic ossification (HO) is a well-known postoperative complication of hip arthroscopy that can lead to pain, limited range of motion, and, in advanced cases, the need for revision surgery. Nonsteroidal anti-inflammatory drugs (NSAIDs), including diclofenac and indomethacin, are widely used for HO prophylaxis. However, there is no consensus on the optimal agent, dosage, and duration of administration.Hypothesis/Purpose:This study aims to compare the efficacy of diclofenac and indomethacin administered for different durations in preventing HO after hip arthroscopy and to evaluate the impact of varying treatment regimens on postoperative clinical outcomes. It was hypothesized that both diclofenac and indomethacin would effectively prevent HO, with no significant difference in HO incidence between them or with prolonged treatment.Study Design:Cohort study; Level of evidence, 3.Methods:A retrospective, multicenter study included 1084 patients who underwent hip arthroscopy for femoroacetabular impingement (FAI) between January 2017 and December 2024. Patients were categorized according to the prophylaxis protocol administered: diclofenac 75 mg for 15 days or indomethacin 75 mg for 15, 30, or 45 days daily. The presence and grade of HO were evaluated according to the Brooker classification. Functional outcomes were assessed pre- and 3, 6, 9, and 12 months postoperatively using the visual analog scale for pain (VAS-Pain) and the Hip Outcome Score–Activities of Daily Living (HOS-ADL).Results:No significant difference in HO development was observed among the study groups (P = .061), with an overall grade 0 rate of 97.7%. The 45-day indomethacin regimen provided superior postoperative pain control with the mean postoperative VAS-Pain score of 0.5 ± 0.4. In contrast, the 15-day diclofenac and indomethacin regimens achieved the greatest improvement, with mean differences in VAS-Pain scores of 5.4 ± 1.6 and 6.8 ± 0.7, respectively. However, the highest postoperative HOS-ADL score was observed in the 15-day indomethacin group (90.4 ± 2.2), whereas the greatest improvement in HOS-ADL was observed in the 30-day group (47.1 ± 3.9), followed by the diclofenac regimen (47 ± 3.8).Conclusion:The incidence and severity of HO did not differ significantly among diclofenac and indomethacin prophylaxis regimens after hip arthroscopy. Prolonging indomethacin prophylaxis beyond 15 days was not associated with a lower rate of HO. These findings suggest that longer NSAID prophylaxis protocols may not provide additional benefit for HO prevention compared with shorter regimens.Keywords: diclofenac, femoroacetabular impingement, heterotopic ossification, hip arthroscopy, indomethacin, nonsteroidal anti-inflammatory drugs prophylaxis Hip arthroscopy is a minimally invasive surgical technique used to manage various hip joint pathologies, most commonly femoroacetabular impingement (FAI). As awareness and understanding of this condition continue to grow among health care professionals, FAI diagnosis and surgical treatment are becoming increasingly frequent.17,19 Although hip arthroscopy is a widely applied method with proven clinical efficacy, it is associated with complication rates of up to 8% to 9%.22,23,39,41 Complications such as chondral damage, labrum retears, nerve injuries, iatrogenic instability, and heterotopic ossification (HO) can negatively affect postoperative outcomes.7,9,27,34 Among these, HO draws attention because it is associated with postoperative pain, movement restriction, and the need for revision surgery in advanced cases.28,32 According to the literature, the reported incidence of HO after hip arthroscopy ranges from 0% to 44%, depending on surgical techniques, patient factors, and postoperative treatment protocols.4,18 Postoperative development of HO is linked to multiple risk factors, including male sex, a history of HO in either hip, ankylosing spondylitis, obesity, advanced age, and the presence of osteoarthritis.1,5 To prevent HO, postoperative prophylaxis with nonsteroidal anti-inflammatory drugs (NSAIDs) is widely used. NSAIDs suppress osteoblastic activity by inhibiting prostaglandin synthesis and thus prevent heterotopic bone formation. 20 Indomethacin historically is the most studied agent, typically administered as 25 mg 3 times daily for 3 to 6 weeks, and meta-analyses have demonstrated its efficacy in reducing low-grade HO (Brooker I-II) in patients undergoing hip arthroplasty. 37 Several cohort/retrospective studies and reviews report a lower incidence of HO in hip arthroscopy patients receiving NSAID prophylaxis, but high-quality randomized controlled trials (RCTs) comparing different agents and durations after arthroscopy are scarce, which limits firm recommendations about an “optimal” regimen for arthroscopy patients.3,11,40 Consequentially, there is no universally accepted single “best” dose-duration for hip arthroscopy; some centers may use a duration of <1 week of an NSAID (diclofenac or indomethacin), while others may use similar medications for >30 days in higher-risk cases, but these choices are not backed by large RCTs. This study aimed to compare the effectiveness of diclofenac and indomethacin in HO prophylaxis and to evaluate the effect of different indomethacin treatment durations. It was hypothesized that both diclofenac and indomethacin would effectively prevent HO when used postoperatively for 15 days, with no significant difference in prophylactic efficacy between them or with longer indomethacin treatment. Methods This was a retrospective, comparative, multicenter study of patients who underwent hip arthroscopy to treat FAI between January 2017 and December 2024. A total of 1084 patients were included. The Institutional Review Board of Istanbul University (Istanbul Faculty of Medicine Clinical Research Ethics Committee No: 2025/854) approved the study protocol. All medical records were obtained from hospital computer databases. Data regarding patient age, sex, body mass index (BMI), diagnosis, date of surgery, surgery procedure performed, and discharge prescriptions were collected. Inclusion criteria were patients aged 15 to 55 who underwent hip arthroscopy with a diagnosis of FAI and were monitored for at least 12 months postoperatively. The diagnosis of FAI was established based on clinical symptoms, physical examination findings, and radiographic criteria. 15 Typically, patients presented with a history of hip pain, which was aggravated during the FADIR test. Imaging studies revealed characteristic features such as a decreased femoral head-neck offset, indicative of cam-type impingement; a lateral center-edge angle (LCEA) <35°, suggestive of pincer-type impingement; and a labral tear. Adequate radiographic follow-up was defined as having both anteroposterior (AP) and Dunn view radiographs of the operated hip at least 12 months after surgery. Exclusion criteria were patients with a history of revision hip arthroscopy, contraindications (eg, NSAID allergy, renal insufficiency, active peptic ulcer disease, or gastrointestinal bleeding) to use prophylactic agents, incomplete medical records, inadequate radiographic follow-up, significant chondral degeneration (Tönnis II changes or greater), LCEA <25° (dysplastic hips), previous hip surgery, or existing HO at presentation. Patients with <12 months of follow-up were also excluded from the study. A history of gastrointestinal complications or discomfort related to NSAID use, a documented allergy to any NSAID, renal insufficiency, and the presence of cardiovascular disease were considered contraindications for NSAID prophylaxis throughout the study period. Surgical Procedure Hip arthroscopic surgery was performed using the Hip Distraction System (Arthrex) with the patient in a modified supine position. The 3-portal approach was used (anterolateral, mid-anterior, and distal anterolateral), and a posterolateral portal was added when necessary. A T-capsulotomy was routinely performed. A diagnostic arthroscopic examination was always performed to assess labral, cam, and pincer abnormalities. Intraoperatively, the labrum was categorized according to the classification system of Seldes et al, 35 and the acetabular labrum articular disruption grading system. All cases required labrum repair, femoroplasty for cam lesions, and acetabular rim trimming or acetabuloplasty for pincer lesions. Microfracture was performed based on surgeon preference. The number of anchors used for each patient ranged from 3 to 7. The labral loop technique and labral base technique were used to repair all labrums. Capsule repair was carried out in all patients, and the vertical limb of T-capsulotomy was completely repaired. 36 The surgical procedures were performed by 3 highly experienced surgeons (A.K., B.K., and G.P.) who specialize in high-volume hip arthroscopic surgery, each with a track record of >500 cases before the commencement of this study.16,25,30 Postoperative Rehabilitation The postoperative rehabilitation protocol was standardized for all patients. Physical therapy was initiated during the first postoperative week with active and passive range of motion exercises. Toe-touch weightbearing was allowed immediately after surgery with the use of forearm crutches. Physical therapy was continued for 4 to 6 weeks, focusing on strengthening exercises and functional activities. Patient-reported outcomes were collected at postoperative visits of 3, 6, 9, and 12 months and yearly thereafter. Return to athletic activities was permitted progressively within 3 to 6 months after the operation. Treatment Groups The patients included in the study were divided into 4 treatment groups according to the postoperative prophylaxis protocols applied: Diclofenac 75 mg for 15 days and indomethacin 75 mg for 15-, 30-, and 45-day daily. Prophylaxis was administered orally, starting within 24 hours postoperatively. Before discharge, patients were instructed on the importance of adhering to HO prophylaxis throughout the treatment period, as prescribed in the postoperative protocol. The treatment protocols were determined based on surgeon preference. These regimens were used consistently during the study period according to each surgeon's routine practice. Data Collection The presence, size, and location of HO were evaluated by radiography with AP and Dunn views of the hip at the 3-month, 6-month, and first-year postoperative follow-up. The presence of HO was reviewed independently by 2 authors (E.Y., T.K.Y.) and graded using the Brooker classification as previously described in the hip arthroplasty literature. Grade 1 is characterized by small, ossified formations within the soft tissues, whereas grade 2 involves ossified structures located between the pelvis and femur, with a bone-to-bone separation exceeding 1 cm. Grade 3 includes ossified formations that reduce the space between the pelvis and femur to <1 cm, whereas grade 4 represents complete hip ankylosis. 6 Clinical evaluation of the patients was made using the visual analog scale for pain (VAS-Pain) and Hip Outcome Score–Activities of Daily Living (HOS-ADL) scores pre- and 3, 6, 9, and 12 months postoperatively, performed by a single author (M.K.). Statistical Analysis Continuous variables were described as the mean ± standard deviation unless stated otherwise. Categorical variables were expressed as n (%). Continuous variables were compared with an independent samples t test for normally distributed quantitative data and a Wilcoxon rank-sum test for non-normally distributed quantitative data. Categorical variables were compared by the chi-square test without the Yates correction for observations with expected frequencies of ≥5 and with the Fisher exact test for observations with expected frequencies of <5. P < .05 was considered statistically significant. All statistical analyses were performed using R Statistical Software (R Version 4.5.1; R Foundation for Statistical Computing). A priori sample size calculation was performed for a 1-way analysis of variance with 4 treatment groups based on HOS-ADL values, assuming a standard deviation of 7, an anticipated mean difference of 10 points, a 2-sided alpha level of .05, and a statistical power of 80%. This analysis indicated that a minimum of 26 samples per group (N = 104) would be required to detect a statistically significant difference among groups. Furthermore, the minimal clinically important difference (MCID) for the HOS-ADL based on the literature was determined to be 9.7 at 2 years postoperatively; this was used to calculate the number of patients achieving MCID after surgery. 29 Results A total of 1084 patients (581 men and 503 women; mean age, 41.88 years) were included in the final analysis. There were 4 treatment groups: diclofenac, 75 mg for 15 days (n = 516); indomethacin, 75 mg for 15 days (n = 96); indomethacin, 75 mg for 30 days (n = 256); and indomethacin, 75 mg for 45 days (n = 216) (Figure 1). Flow diagram of patients included in the study. FAI, femoroacetabular impingement; HO, heterotopic ossification; LCEA, lateral center-edge angle; NSAID, nonsteroidal anti-inflammatory drug. A significant difference was found in the mean age of the study groups (P = .001). The mean age was higher in the diclofenac group than in the 15-, 30-, and 45-day indomethacin groups (Table 1). The mean follow-up duration was 30.94 months, and the follow-up times were similar between the groups. In terms of BMI, groups were similar except that the indomethacin for 15 days group had a lower BMI (21.65 ± 1.5 kg/m2) compared with the other groups (P = .001). Significant differences were also observed in LCEA and alpha angles (both P < .001) (Table 1). Table 1Patient Characteristics by Group a Diclofenac,15 Daysn = 516Indomethacin,15 Days,n = 96Indomethacin,30 Days,n = 256Indomethacin,45 Days,n = 216 P Female sex242 (46.9)41 (42.7)122 (47.7)98 (45.3)≥.999Age, years45.7 ± 11.941.5 ± 6.537 ± 7.238.6 ± 10.3<.001BMI, kg/m227.8 ± 621.6 ± 1.526.6 ± 6.126.9 ± 3.8<.001LCEA, deg35.6 ± 8.240.9 ± 5.232.9 ± 3.132.5 ± 7.6<.001Alpha angle, deg75.9 ± 9.866.6 ± 5.259.6 ± 4.361.2 ± 12<.001aData are presented as mean ± SD or n (%). BMI, body mass index; LCEA, Lateral center edge angle. Patient Characteristics by Group a Data are presented as mean ± SD or n (%). BMI, body mass index; LCEA, Lateral center edge angle. According to the Brooker classification, no significant difference was found between the groups regarding HO development (P = .061). Results are presented in Table 2. Table 2Distribution of Postoperative Heterotopic Ossification Grades Among Study Groups According to the Brooker Classification a GroupGrade 0Grade 1Grade 2Grade 3Grade 4Total Count P GradeDiclofenac, 15 days5059110516.061% within group97.91.70.20.20100Indomethacin, 15 days91311096% within group94.73.1110100Indomethacin, 30 days2533000256% within group98.81.2000100Indomethacin, 45 days2115000216% within group97.72.3000100Total1060202201084% within group97.71.80.20.20100aNo statistically significant differences were observed between groups. Distribution of Postoperative Heterotopic Ossification Grades Among Study Groups According to the Brooker Classification a No statistically significant differences were observed between groups. Preoperative VAS scores were highest in the 15-day indomethacin group (7.7 ± 0.5), and the lowest in the 45-day group (4 ± 1.1). Although the 45-day indomethacin regimen provided the lowest final postoperative VAS scores, the greatest improvement in pain was achieved with the 15-day indomethacin followed by diclofenac regimen. Regarding the final postoperative HOS-ADL score, the highest score was observed in the 15-day indomethacin group. However, the greatest improvement was observed in the 30-day indomethacin group, with a mean score of 86.5 ± 2.2 (P = .001), followed by the diclofenac group. Patient-reported outcome scores were also presented (Table 3). All groups demonstrated significant postoperative improvements in VAS and HOS-ADL scores (Table 4). Table 3Patient-Reported Outcomes in the 4 Groups a PROsDiclofenac, 15 DaysIndomethacin, 15 DaysIndomethacin 30 DaysIndomethacin, 45 Days P b PreopPostopPreopPostopPreopPostopPreopPostopPreopPostopVAS-Pain7.2 ± 11.77 ± 1.37.7 ± 0.50.9 ± 0.75.6 ± 11.5 ± 0.64 ± 1.10.5 ± 0.45 .001 .001 HOS-ADL39.6 ± 3.586.6 ± 247.3 ± 2.790.4 ± 2.239.4 ± 3.386.5 ± 2.244.3 ± 7.288.3 ± 7.3 .001 .001 aData are presented as mean ± SD. Boldface P values indicate statistical significance. HOS-ADL, Hip Outcome Score-Activities of Daily Living; Postop, postoperative; Preop, preoperative; PRO, patient-reported outcome; VAS, visual analog scale.bThe Preop P value represents the overall comparison of preoperative scores across all 4 Preop groups, whereas the Postop P value represents the overall comparison of postoperative scores across all 4 Postop groups. Patient-Reported Outcomes in the 4 Groups a Data are presented as mean ± SD. Boldface P values indicate statistical significance. HOS-ADL, Hip Outcome Score-Activities of Daily Living; Postop, postoperative; Preop, preoperative; PRO, patient-reported outcome; VAS, visual analog scale. The Preop P value represents the overall comparison of preoperative scores across all 4 Preop groups, whereas the Postop P value represents the overall comparison of postoperative scores across all 4 Postop groups. Table 4Mean Changes in VAS-Pain and HOS-ADL Scores Across Prophylaxis Groups a Diclofenac,15 DaysIndomethacin,15 DaysIndomethacin,30 DaysIndomethacin,45 Days P VAS-Pain difference, preop-postop5.4 ± 1.66.8 ± 0.74 ± 1.13.5 ± 1 .001 HOS-ADL difference, postop-preop47 ± 3.842.8 ± 3.547.1 ± 3.943.6 ± 5.3 .001 aData are presented as mean ± SD. Boldface P values indicate statistical significance. HOS-ADL, Hip Outcome Score-Activities of Daily Living; Postop, postoperative; Preop, preoperative; VAS, visual analog scale. Mean Changes in VAS-Pain and HOS-ADL Scores Across Prophylaxis Groups a Data are presented as mean ± SD. Boldface P values indicate statistical significance. HOS-ADL, Hip Outcome Score-Activities of Daily Living; Postop, postoperative; Preop, preoperative; VAS, visual analog scale. Based on the final postoperative HOS-ADL MCID evaluation, the percentages of patients achieving MCID were 99.6%, 100%, 99.6%, and 100%, respectively, in the diclofenac 15-day, indomethacin 15-day, 30-day, and 45-day groups. Based on thresholds defined by Beck et al, 2 a decrease of >14.8 points in VAS-Pain score was considered the MCID after hip arthroscopy for FAI. According to this criterion, the proportion of patients achieving the VAS MCID was 97.9%, 99%, 98.7% and 99.5% in the diclofenac 15-day, indomethacin 15-, 30- and 45-day groups, respectively. Discussion The most important finding of the study was that the use of different pharmacological prophylaxis protocols did not significantly differ in terms of HO development after hip arthroscopy. All prophylaxis protocols demonstrated significant improvements in VAS-Pain and HOS-ADL scores compared with preoperative values. Nearly all patients in all groups exceeded the MCID threshold for HOS-ADL, and a similar trend was observed for VAS-Pain scores. Although HO is relatively uncommon after arthroscopic procedures, it can lead to significant functional limitations, especially in young and active individuals who had arthroscopic FAI surgery. 31 Given the increasing use of arthroscopic osteochondroplasty, evaluating the role of NSAID prophylaxis in reducing the risk of HO is of high importance. HO refers to the pathological development of bone within soft tissues where bone does not normally exist. Its development is driven by a complex interplay of factors, including surgical trauma, inflammatory responses, and the activation of osteogenic precursor cells.4,13 Our patient population demonstrated 2.2% HO after hip arthroscopy, which is on the lower end of the reported values. Most patients with postoperative HO remain asymptomatic, and the condition is typically detected as an incidental finding on radiographic evaluations.5,13 NSAIDs and low-dose radiotherapy are the most widely used methods for preventive intervention to reduce the incidence of HO.20,38,40 Indomethacin was first reported by Dahl as a potential prophylactic agent for preventing HO, and its effectiveness has been validated in multiple subsequent studies.8,10,12,37 However, several reports in the literature question its efficacy.21,24,26,37 Our findings align with previous studies reporting low rates of HO in patients receiving NSAID prophylaxis after hip arthroscopy. Retrospective studies have demonstrated similar incidences of HO after hip arthroscopy, regardless of variations in NSAID prophylaxis duration. Randelli et al 31 reported an absence of HO in a cohort of 285 patients who received a 3-week course of NSAID prophylaxis after undergoing hip arthroscopy for FAI. Furthermore, studies have indicated that administering indomethacin for 4 days, followed by a 30-day course of naproxen, reduced the incidence of HO to 1.8% in patients undergoing primary hip arthroscopy. 4 Beckmann et al 4 reported a reduction in the incidence of HO from 25% in patients who did not receive NSAID prophylaxis to 5.6% in those who received NSAID prophylaxis for 3 weeks postoperatively. Similarly, Rath et al 33 reported no HO cases in a cohort of 63 patients who underwent a 2-week etodolac prophylaxis initiated on the first postoperative day. However, uncertainty continues regarding the most appropriate agent, dosage, and duration of administration. Beckmann et al 3 suggested that short-term NSAID prophylaxis may be inadequate in suppressing ectopic bone formation. In contrast, our findings showed no significant differences in HO development among the groups. Informing patients about the potential benefits and risks of NSAIDs is important for patient compliance with the treatment. Our findings confirm the effectiveness of NSAID prophylaxis. Although the adverse effects of short-term NSAID prophylaxis are less clearly defined than those associated with prolonged use, potential complications should still be taken into consideration. Long-term NSAID use may be associated with gastrointestinal complications such as peptic ulcer and upper gastrointestinal bleeding. It may also increase the risk of renal failure, especially in patients with preexisting renal dysfunction.3,14 Therefore, considering these risks, the potential benefits of long-term prophylaxis must be carefully evaluated. Future studies should focus on defining patient groups based on individual risk profiles to optimize the balance between efficacy and safety. While pharmacologic prophylaxis has been shown to be important in preventing HO, surgical technique may also have an impact. Regarding surgical technique, meticulous removal of bone debris during hip osteochondroplasty is essential for mitigating HO risk. Any residual bone fragments may be a focal point for ectopic bone formation. 3 Beckmann et al 3 found an increased incidence of HO in patients who underwent acetabuloplasty in conjunction with osteochondroplasty. Therefore, dedicating sufficient time during surgery to remove all accessible bone remnants after osteochondroplasty may be one of the key surgical strategies for minimizing the risk of HO formation. The major strengths of this study are the large, multicenter cohort (n = 1084) and the evaluation of 4 clinically relevant prophylaxis protocols (diclofenac for 15 days; indomethacin for 15, 30, and 45 days) under a standard surgical and rehabilitation protocol by high-volume surgeons. This design allowed comparisons of both the incidence of HO and patient-reported outcomes. We found no significant difference in the development of HO between protocols, indicating comparable efficacy of all regimens. Similar improvements in pain and functional recovery were observed among groups. There were some limitations in this study. First, since it was a retrospective study, it carries inherent risks such as selection bias and confounding variables. Treatment allocation was not randomized and was based on surgeon preference, and there were no predefined indications for prolonged indomethacin prophylaxis. Second, although all surgeons were high-volume hip arthroscopy surgeons, differences in surgical technique, including the extent of bony debris removal and irrigation, may have influenced HO formation. Third, this study evaluated only 2 NSAID agents, diclofenac and indomethacin, and therefore the findings may not be generalizable to other commonly used agents such as naproxen. Fourth, the shortest prophylaxis duration evaluated was 15 days. Therefore, this study cannot determine whether shorter NSAID regimens would provide similar HO prophylaxis. Fifth, NSAID-related side effects and complications could not be reliably analyzed. Patients who were unable to complete the prescribed prophylaxis protocol were excluded from the final analysis. However, the specific reasons for discontinuation, including possible NSAID intolerance or adverse events, were not consistently documented. Finally, although the Brooker classification is widely used for evaluating HO, radiographs may miss early or subtle ossification that could be detected with advanced imaging. Future prospective randomized studies comparing different NSAID agents and shorter prophylaxis durations, while systematically assessing adverse events, are needed to define the optimal HO prophylaxis protocol after hip arthroscopy. Conclusion The incidence and severity of HO did not differ significantly between diclofenac and indomethacin prophylaxis regimens after hip arthroscopy. Prolonging indomethacin prophylaxis >15 days was not associated with a lower rate of HO. These findings suggest that longer NSAID prophylaxis protocols may not provide additional benefit for HO prevention compared with shorter regimens. These results may help define practical NSAID prophylaxis durations and guide future comparative studies. Footnotes Final revision submitted July 18, 2026; accepted July 25, 2026. The authors have declared that there are no conflicts of interest in the authorship and publication of this contribution. Ethical committee approval for this study was obtained from the Research Ethics Commission of Istanbul University (No. 2025/854). ORCID iDs: Muge Kirac https://orcid.org/0009-0005-5615-7087 Baris Kocaoglu https://orcid.org/0000-0002-2537-0660 References